

Re: Your request made under the Freedom of Information Act 2000

Please see below a Freedom of Information request made by OPEN Health. Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.

1. Do you treat patients with acute myeloid leukaemia (AML) in your Trust?

Answer: **YES**

If yes, please proceed to Question 3, if no, please answer Question 2

2. Where do patients diagnosed with AML in your Trust receive treatment?

Answer:

3. Please complete the table below with how many newly diagnosed patients with AML have started first-line treatment with each of the following therapies during the 6-month period October 2023 to March 2024?
 - Azacitidine monotherapy
 - Low dose cytarabine (LoDAC) monotherapy
 - Venetoclax + azacitidine
 - Venetoclax + LoDAC
 - Ivosidenib
 - Intensive chemotherapy-based regimen
 - Examples include: cytarabine and daunorubicin, idarubicin, fludarabine, mitoxantrone, etoposide (VP-16), 6-thioguanine (6-TG), methotrexate (MTX) or 6-mercaptopurine (6-MP), gemtuzumab ozogamicin with daunorubicin cytarabine, or FLAG-Ida (fludarabine, cytarabine, granulocyte-colony stimulating factor and idarubicin)
 - Best supportive care
 - Other
 - Do not include prophylactic therapies such as GCSF, anti-fungals, antihistamines, anti-nauseants

Note: this should only include patients with AML who have started first-line treatment during the 6-month window

Answer:

Treatment option	Number of newly diagnosed patients with AML starting first line treatment during the 6-month period October 2023 to March 2024
Azacitidine monotherapy	2
(LoDAC) monotherapy	0
Venetoclax + azacitidine	5
Venetoclax + LoDAC	0
Ivosidenib	0
Intensive chemotherapy-based regimen	3
Best supportive care	<i>Not shown on our Pharmacy data System</i>
Other	

